Azurity Pharmaceuticals, Inc

ImmunoMolecular Therapeutics, Inc., based in Woburn, MA, is pioneering the development of novel personalized medicines aimed at treating autoimmune diseases through a targeted drug design approach. The company is focused on building an HLA-directed platform for new therapies, demonstrating early effectiveness in conditions such as type 1 diabetes while expanding its pipeline across various autoimmune disorders. Utilizing innovative therapies that specifically block the action of HLA proteins involved in triggering autoimmune responses, ImmunoMolecular Therapeutics is committed to transforming lives through its patient-centered approach. The company has garnered attention for its promising early results in clinical trials and for its leadership in the field of autoimmune disease therapeutics. Generated from the website

ChemGenes Corporation, a biotechnology company, recently relocated to a state of the art facility in Wilmington, Massachusetts. We have consistently been a strong partner to researchers engaged in the field of DNA/RNA synthesis for 23 years. By starting out as a supplier of 'Ultra Pure Products' and then also by becoming an active Contract Researcher, ChemGenes Corporation has achieved unparalleled expertise in the field of DNA/RNA synthesis. Thus, all of us at ChemGenes have the opportunity and great pleasure to serve a vast number of scientists in the US and all over the world.ChemGenes' product lines include phosphoramidites for RNA and DNA synthesis, Antisense phosphoramidites, modified bases for DNA, as well as RNA modification. In addition, we produce a variety of modified phosphoramidites for the introduction of chromophores and ligands. The availability of prepacked disposable columns of various pore sizes, loadings, low volume columns, ancillary reagents in configurations suitable for each synthesizer, and DNA purification cartridges is another way ChemGenes meets its customers needs.A large variety of Reagents for the synthesis of DNA/RNA are also available, which include many natural and modified nucleoside bases, tetrazole, 5-thioethyltetrazole, DMT-chloride, DMT protected deoxy and ribo nucleosides, 2'-O-methyl and 2'-O-propargyl nucleosides, silyl protected ribonucleosides, several types of phosphorylating reagents, and many more.

Rgenta Therapeutics, Inc., based in Woburn, MA, is a clinical-stage biotechnology company focused on developing innovative RNA-targeting oral small molecules for hard-to-treat diseases, particularly in oncology and central nervous system (CNS) disorders. By leveraging proprietary genomic data analysis, Rgenta aims to design and optimize potent RNA-targeting drugs that can effectively modulate splicing and gene expression, addressing previously undruggable targets. The company's pioneering approach enhances the stability of RNA interactions with splicing machinery, leading to the degradation of pathological target proteins. Rgenta is committed to transforming the treatment landscape for incurable diseases by unlocking new therapeutic possibilities through its RNA-targeted therapies. Generated from the website